Exchange: NASDAQ·Updated 05:33 AM EDT

NTLA Earnings

Latest Earnings Results: Q2 '26

Reported: Aug 06

Estimated EPS

-$0.80

Reported EPS

-$0.80

Surprise

-0.09%

Estimated Rev

$12.98M

Reported Rev

$7.66M

Surprise

-40.99%

• Reported GAAP EPS of -$0.80 up 18.37% YoY • Reported revenue of $7.66M down -46.23% YoY • Intellia Therapeutics expects FDA acceptance of its biologics license application for lonvo-z in the second half of 2026 and plans to launch lonvo-z commercially in the first half of 2027.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.80
--
--
N/A
Q2 '26
-$0.80
-$0.80
-0.09%
MISSED
Q1 '26
-$0.91
-$0.81
11.06%
BEAT
Q4 '25
-$0.94
-$0.83
11.81%
BEAT
Q3 '25
-$1.01
-$0.92
8.50%
BEAT

Advertisement|Remove ads.